Jeffrey Huang, DO
Ophthalmology · San Marino, CANPI 1124274998
Payments from drug & device makers
Across 220 payments — averaging $119.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Alcon$1K
- Bausch & Lomb Americas Inc.$915
- Tarsus Pharmaceuticals, Inc.$356
- AbbVie$315
- Sun Pharmaceutical Industries Inc.$315
- plus $1K from 15 others
What the payments were for
- Consulting fees$4,65018%
- Speaking & faculty fees$15,20058%
- Travel & lodging$9474%
- Food & beverage$5,47721%
- Education$100%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 72 | $21,966 |
| Alcon | 36 | $1,322 |
| Bausch & Lomb Americas Inc. | 28 | $915 |
| Tarsus Pharmaceuticals, Inc. | 11 | $356 |
| AbbVie(2 entities) | 20 | $315 |
| Sun Pharmaceutical Industries Inc. | 12 | $315 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $183 |
| Rxsight Inc | 2 | $161 |
| Harrow Eye, LLC | 4 | $121 |
| Oyster Point Pharma, Inc. | 5 | $107 |
| Aerie Pharmaceuticals, Inc. | 5 | $98 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $68 |
| Novartis | 3 | $66 |
| Glaukos Corporation | 2 | $61 |
| Dompe US, Inc. | 2 | $57 |
| Sight Sciences, Inc. | 3 | $51 |
| Ivantis, Inc | 2 | $46 |
| Thea Pharma Inc. | 2 | $45 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$18,859
- AMVISC$335
- enVista MX60 IOL$335
- NGENUITY$296
- Clareon$253
- ARGOS$157
- Luxor$150
- RXSIGHT CONTACT LENS$145
- RXSIGHT INJECTOR HANDPIECE$145
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$145
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$145
- RXSIGHT INJECTOR CARTRIDGE$145
- PROLENSA$117
- XDEMVY$101
How this compares
$26,303 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 302 | $118,875 |
| RestasisCyclosporine | 157 | $107,776 |
| XiidraLifitegrast | 115 | $76,808 |
| VyzultaLatanoprostene Bunod | 76 | $35,475 |
| Cyclosporine | 79 | $33,618 |
| BesivanceBesifloxacin Hcl | 89 | $19,157 |
| Alphagan PBrimonidine Tartrate | 49 | $14,166 |
| Bromfenac Sodium | 70 | $12,453 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,261 |
| RhopressaNetarsudil Mesylate | 27 | $9,829 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $9,675 |
| Prednisolone Acetate | 321 | $8,365 |
| RocklatanNetarsudil Mesylat/Latanoprost | 23 | $7,723 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $6,903 |
| Brimonidine Tartrate | 40 | $6,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $315 | $250,492540 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $915 | $122,544205 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Istalol, Loteprednol Etabonate | $183 | $29,605134 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $98 | $17,55350 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $315 | $4,45618 claims |
| AlconSimbrinza | $1,322 | $3,12217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Marino
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.